New strategies which improve the efficacy of radiation therapy and/or protect surrounding normal tissue from damage can have a major impact on treatment outcome. Recent studies have reinvigorated the hypothesis that the outcome of radiation therapy is dependent upon the anti-tumor immune response and strongly support the testing of new combinations of ionizing radiation with immunotherapy. Heat shock protein (HSP) biology has been central to our research for many years. This work led to a completely new vaccine paradigm based upon the chaperone potential of large HSPs (first discovered by our group) and their ability to stimulate powerful anti-tumor immunity. Large HSPs, including hsp110 and the glucose regulated protein 170 (grp170) are related molecular chaperones that are highly efficient in binding to large substrate proteins. Our team has demonstrated that clinically relevant tumor antigens (e.g., gp100, HER- 2/neu, etc.) can be complexed to these large stress-response proteins by heat shock generating a highly effective antigen-specific, immune response. In a significant demonstration of lab bench-to-bedside research, our preclinical results led to a successful RAID application from the NCI for the development of a novel hsp110-based vaccine now undergoing Phase I evaluation in advanced melanoma patients. In new preliminary and published data, we have discovered that grp170 and pathogen-associated molecules (PAMPs) can act synergistically to stimulate the innate immune response and this is dependent on the chaperoning activity of grp170. We believe that this discovery can result in a novel, multipronged approach to cancer therapy. Therefore, we have engineered a chimeric chaperone, termed Flagrp170, by fusing a truncated grp170 chaperone with bacterial flagellin-derived PAMP which has an NF-kB-activating domain. Since preliminary data show a strong potential for Flagrp170 to provide a radioprotective effect, we hypothesize that this novel agent could both enhance therapeutic responsiveness to ionizing radiation (through enhanced immune responses of the vaccine) and provide critical protection of normal tissue. We will test our hypothesis in three specific aims.
In Aim 1, we predict that this chaperoning competent chimeric macromolecule can preferentially deliver selected antigens to specialized antigen-presenting cells and concurrently stimulate the NF-kB signaling for their functional activation.
In Aim 2, we will test whether vaccination with Flagrp170 complexed with tumor antigen will generate a more potent and durable immune response than unmodified grp170.
In Aim 3, the potential of using Flagrp170 to improve efficacy of ionizing radiation and provide tissue protection against radio-toxicity will be investigated. Successful completion of proposed research will not only provide a better understanding of the multifunctional features of the chimeric chaperone, but will also establish a scientific rationale for design the new generation of HSP-based vaccines to be used alone or in conjunction with the standard-of-care therapies (e.g., radiotherapy) in future clinical trials.

Public Health Relevance

While radiation and other cancer therapies can result in impressive short-term effects on tumor growth, in many patients the tumor cells become resistant and develop more aggressive growth and metastasis. Developing innovative antitumor therapeutics that stimulate long-term immune control (the goal of this application) with high effectiveness and less toxicity offer potential for improving the long-term survival and quality of life in cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
3R01CA099326-24S1
Application #
9840994
Study Section
Radiation Therapeutics and Biology Study Section (RTB)
Program Officer
Buchsbaum, Jeffrey
Project Start
2017-08-15
Project End
2019-08-14
Budget Start
2018-08-15
Budget End
2019-08-14
Support Year
24
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Ma, Yibao; Temkin, Sarah M; Hawkridge, Adam M et al. (2018) Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett 435:92-100
Menezes, Mitchell E; Bhoopathi, Praveen; Pradhan, Anjan K et al. (2018) Role of MDA-7/IL-24 a Multifunction Protein in Human Diseases. Adv Cancer Res 138:143-182
Payne, Kyle K; Aqbi, Hussein F; Butler, Savannah E et al. (2018) Gr1-/low CD11b-/low MHCII+ myeloid cells boost T cell anti-tumor efficacy. J Leukoc Biol 104:1215-1228
Emdad, Luni; Das, Swadesh K; Wang, Xiang-Yang et al. (2018) Cancer terminator viruses (CTV): A better solution for viral-based therapy of cancer. J Cell Physiol 233:5684-5695
Guo, Chunqing; Subjeck, John R; Wang, Xiang-Yang (2018) Creation of Recombinant Chaperone Vaccine Using Large Heat Shock Protein for Antigen-Targeted Cancer Immunotherapy. Methods Mol Biol 1709:345-357
Tang, Yuan; Li, Huifang; Li, Junru et al. (2017) Macrophage scavenger receptor 1 contributes to pathogenesis of fulminant hepatitis via neutrophil-mediated complement activation. J Hepatol :
Bucsek, Mark J; Qiao, Guanxi; MacDonald, Cameron R et al. (2017) ?-Adrenergic Signaling in Mice Housed at Standard Temperatures Suppresses an Effector Phenotype in CD8+ T Cells and Undermines Checkpoint Inhibitor Therapy. Cancer Res 77:5639-5651
Pagare, Piyusha P; Zaidi, Saheem A; Zhang, Xiaomei et al. (2017) Understanding molecular interactions between scavenger receptor A and its natural product inhibitors through molecular modeling studies. J Mol Graph Model 77:189-199
PrabhuDas, Mercy R; Baldwin, Cynthia L; Bollyky, Paul L et al. (2017) A Consensus Definitive Classification of Scavenger Receptors and Their Roles in Health and Disease. J Immunol 198:3775-3789
Zheng, Yi; Li, Xia; Pagare, Piyusha P et al. (2017) Design, synthesis, and characterization of rhein analogs as novel inhibitors of scavenger receptor A. Bioorg Med Chem Lett 27:72-76

Showing the most recent 10 out of 43 publications